Public Profile

Cosmo Pharmaceuticals N.V.

Cosmo Pharmaceuticals N.V., a leading biopharmaceutical company headquartered in Ireland (IE), focuses on developing innovative treatments for gastrointestinal diseases and other specialised areas. Founded in 1997, Cosmo has established a strong presence in Europe and the United States, with significant operational activities in these key markets. The company is renowned for its unique drug delivery technologies, particularly in the field of endoscopy and gastrointestinal health. Its flagship products, including the advanced bowel preparation agent and proprietary drug formulations, set Cosmo apart in the competitive pharmaceutical landscape. With a commitment to research and development, Cosmo Pharmaceuticals has achieved notable milestones, positioning itself as a trusted name in the biopharmaceutical industry.

DitchCarbon Score

How does Cosmo Pharmaceuticals N.V.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

25

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Cosmo Pharmaceuticals N.V.'s score of 25 is lower than 61% of the industry. This can give you a sense of how well the company is doing compared to its peers.

39%

Let us know if this data was useful to you

Cosmo Pharmaceuticals N.V.'s reported carbon emissions

Cosmo Pharmaceuticals N.V., headquartered in Ireland (IE), currently does not have available carbon emissions data for the most recent year, nor does it specify any reduction targets or initiatives. Without specific emissions figures or commitments, it is unclear how the company is addressing its carbon footprint or contributing to climate action. In the absence of concrete data, it is essential for stakeholders to monitor future disclosures regarding Cosmo Pharmaceuticals' climate commitments and sustainability strategies.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Cosmo Pharmaceuticals N.V.'s primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Cosmo Pharmaceuticals N.V. is in IE, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Cosmo Pharmaceuticals N.V. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

Clinigen

GB
Pharmaceutical Preparation Manufacturing
Updated 21 days ago

STADA Arzneimittel Aktiengesellschaft

DE
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Basilea Pharmaceutica

CH
Health and social work services (85)
Updated 21 days ago

RECORDATI

LU
Pharmaceutical Preparation Manufacturing
Updated 8 days ago

Assertio Holdings, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 10 days ago

Faes Farma

ES
Pharmaceutical Preparation Manufacturing
Updated 22 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers